Publications by authors named "V A Doronin"
Article Synopsis
- The study investigated the effectiveness and optimal dosage of cusatuzumab, an anti-CD70 antibody, combined with azacitidine for treating acute myeloid leukaemia in patients not eligible for intensive chemotherapy.
- Conducted across 40 hospitals in seven countries, the randomized trial assigned 103 adult patients to receive either 10 mg/kg or 20 mg/kg doses of cusatuzumab alongside azacitidine in 28-day cycles, aiming to evaluate complete remission rates.
- Although 55% of patients experienced significant treatment results, the study was halted after part one due to changes in the treatment landscape that made continuing with further phases impractical.
The exact mechanisms of multiple sclerosis development are still unknown. However, the development of EAE (experimental autoimmune encephalomyelitis) in Th and 2D2 mice is associated with the infringement of the differentiation profiles of bone marrow hematopoietic stem cells which are bound with the production of compounds that are harmful for human autoantibodies-abzymes that hydrolyze myelin oligodendrocyte glycoprotein, myelin basic protein, and DNA. It showed that autoimmune patients' antioxidant IgG antibodies oxidise some compounds due to their peroxidase (HO-dependent) and oxidoreductase (HO-independent) activities more effectively than those in healthy humans can.
View Article and Find Full Text PDFPANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS; n = 324), higher-risk chronic myelomonocytic leukemia (n = 27), or acute myeloid leukemia (AML) with 20% to 30% blasts (n = 103). The primary end point was event-free survival (EFS). In the intent-to-treat population, the median EFS was 17.
View Article and Find Full Text PDFArticle Synopsis
- The trial was a phase 3 study comparing enasidenib, an oral IDH2 inhibitor, to standard care regimens in older patients with late-stage acute myeloid leukemia (AML) who had already undergone multiple treatments.
- The primary goal was to evaluate overall survival (OS), but while the OS results were similar (6.5 months for enasidenib vs. 6.2 months for standard care), enasidenib showed significant improvements in secondary outcomes like event-free survival (EFS), overall response rate (ORR), and transfusion independence (TI).
- Despite not meeting the primary endpoint for OS, the findings suggest that enasidenib could offer important benefits in managing relapsed or refractory AML in
The poor prognosis of acute T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in older adults and patients with relapsed/refractory illness is an unmet clinical need, as there is no defined standard of care and there are few treatment options. Abnormally elevated CD38 expression in T-ALL and T-LBL is associated with tumor expansion and disease development, making CD38 a potential target for anti-T-ALL and T-LBL treatment. Isatuximab is a monoclonal antibody that binds to a specific epitope on CD38.
View Article and Find Full Text PDF